Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.

28 May 2001

• By The Pink Sheet

Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.

Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.

More from Archive

More from Pink Sheet